• Skip to main content
  • Skip to footer

Easly

Innovative Financing for Innovators

  • Easly Advances
    • How it Works
    • SR&ED Financing
    • Our Customers
  • About
    • Company
    • Careers
    • Contact
  • Resources
    • Blog
    • News & Events
    • Easly Calculator
    • SR&ED Calculator
    • FAQ
  • Easly Calculator
  • Apply Now
  • CAN
    • UK
Back to Blog
Share on Linkedin Twitter Facebook

Entos Pharmaceuticals COVID-19 Vaccine Prepares for Phase 1 Clinical Trials with Help from Canada’s NRC IRAP Program

30 Apr 2021

Entos Pharmaceuticals COVID-19 Vaccine Prepares for Phase 1 Clinical Trials with Help from Canada’s NRC IRAP Program
Published on: April 30, 2021

Canada’s first COVID-19 case occurred in Toronto on January 25, 2020. Since then, millions of cases have been reported around the world, with over 1 million in Canada alone. Pharmaceutical companies have worked tirelessly to develop effective vaccines in the fight against SARS-CoV-2, including Edmonton, Alberta-based firm Entos Pharmaceuticals. Here, we take a closer look at the role of government R&D funding programs, like the Scientific Research and Experimental Development (SR&ED) tax incentive program and National Research Council Canada Industrial Research Assistance Program (NRC IRAP) for Canada’s healthcare companies.

NRC IRAP-Funded Vaccine Could Be a Global Game-Changer

Five vaccines are currently approved for administration by Health Canada: Pfizer-BioNTech, AstraZeneca, Moderna, Johnson & Johnson (Janssen) and COVIDSHIELD. All of these vaccines were developed outside the country and rely on either mRNA or traditional vaccine technology. While very effective, they have a limited shelf life and require refrigeration and precise handling. This makes the existing vaccines difficult to administer in remote, rural areas and in countries where storage standards simply cannot be met.

Covigenix VAC-001, the COVID-19 immunization currently under development by Entos Pharmaceuticals, has the potential to revolutionize coronavirus vaccination as we know it. As a DNA vaccine, Covigenix VAC-001 works much like its mRNA-driven counterparts. The vaccine reproduces a small fraction of viral DNA, which tells our bodies they are under attack. Production of a specific cellular protein is triggered, activating our immune systems’ antibodies to fight the virus. After a short time, recipients will achieve effective resistance against COVID-19 infection.

A safe and effective DNA vaccine for COVID-19 could be ground-breaking in the domestic and international battles against this global pandemic. Advantages offered by this type of vaccine include:

  • Stability at room temperature for up to 30 days
  • Stability in refrigeration for up to one year
  • Prepared in a ready-to-use concentration

All in all, the Entos Pharmaceuticals vaccine would be easier to store, distribute and administer outside urban centers and in developing nations. With new variants emerging at an alarming pace and global vaccination rates lagging, Covigenix VAC-001 could play a critical role in overcoming COVID-19.

The Role of SR&ED and NRC IRAP Funding in Vaccine Development

Like all innovations, new healthcare preventatives, treatments, and supplies are driven by research and development (R&D) work. These essential activities are often expensive and can be cost-prohibitive for many companies without financial support from government partners.

This support came in the form of $23.2 million in federal funding through NRC IRAP to develop COVID-19 vaccines, treatments, and other medical supplies. Among funds shared by six companies, Entos Pharmaceuticals received approximately $5 million to bring Covigenix VAC-001 to Phase 1 clinical trials. The company hopes to receive additional funding to support Phase 2 clinical trials by late spring of 2021.

Benefits for Public Health and Economic Growth

Companies like Entos Pharmaceuticals cannot complete the extensive R&D work required to create new medical technologies without reliable sources of capital. While all firms may generate revenues from existing products, take on loans, and secure equity investments, creating sufficient capital through these methods alone would be unlikely. The NRC IRAP and SR&ED tax incentive programs bridge this gap with funding that is available before and after costs are incurred for a wide range of qualifying expenditures.

The benefit of these programs stretches far beyond the companies that receive funding. Federal investment in R&D helps position Canada at the forefront of healthcare innovation. Work funded for COVID-19 vaccine development today will better prepare the country’s medical and pharmaceutical development and manufacturing companies for future public health risks with improved technologies, facilities, and processes.

At the same time, SR&ED tax credits and NRC IRAP funding are an investment in the strength and diversity of the Canadian economy. Providing the capital needed to sustain rigorous R&D work across the country will fuel opportunities in the health sciences and pharmaceutical sectors for years to come.

Taking Advantage of SR&ED Tax Credits and NRC IRAP Funding

If your company undertakes eligible R&D activities, it can receive SR&ED tax credits and NRC IRAP funding. While these programs may not be stacked to double benefits, they form part of a capital strategy that makes R&D work more affordable and technological and scientific advancement more achievable.

Additional non-refundable incentives are also available for select companies. When used alongside NRC IRAP grants, SR&ED tax credits reduce the cost and risk of R&D work to help companies like Entos Pharmaceuticals – and yours – contribute to essential innovations across numerous fields.

If your company receives SR&ED tax credits, waiting for a refund can delay the capital required to continue R&D work. Don’t let these delays slow your progress. With our Capital-as-a-Service (CaaS) platform, Easly provides quarterly advances on SR&ED refunds to help innovative Canadian companies receive funds faster.

Contact us today to see how we can streamline the process for your organization.

 

 

COVIDNRC IRAP-FundedVaccination
Contact Us
Share on Linkedin Twitter Facebook
Prev Post
Next Post
COVIDCOVID Funding + SR&ED: How They Work TogetherWorking Through COVID
FinancingWhat is Non-Dilutive Funding (Financing)?A group of people working together
GovernmentTop 5 Canadian Grant & Refund Programs You Should Be UsingA waving Canadian flag in front of the CN Tower

Footer CTA

Easly White Logo
  • Home
  • Easly Advances
    • How It Works
    • SR&ED Financing
    • Our Customers
  • About
    • Company
    • Careers
    • Contact
  • Resources
    • Blog
    • News & Events
    • Easly Calculator
    • SR&ED Calculator
    • FAQ
  • Apply Now

© ESFC Funding Co., LLC 2025
Privacy Policy Terms of Use
Linkedin

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and are used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory for us to procure your consent prior to running these cookies on our website.
SAVE & ACCEPT